0000950170-23-058943.txt : 20231103
0000950170-23-058943.hdr.sgml : 20231103
20231103184933
ACCESSION NUMBER: 0000950170-23-058943
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231101
FILED AS OF DATE: 20231103
DATE AS OF CHANGE: 20231103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lyon Joseph Douglas
CENTRAL INDEX KEY: 0001817838
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 231377752
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2023-11-01
false
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001817838
Lyon Joseph Douglas
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
Chief Accounting Officer
true
Common Stock
2023-11-01
4
M
false
1023
11.35
A
6877
D
Common Stock
2023-11-01
4
S
false
1023
28.08
D
5854
D
Common Stock
2023-11-02
4
M
false
3977
11.35
A
9831
D
Common Stock
2023-11-02
4
S
false
3977
28.1102
D
5854
D
Stock option (right to buy)
11.35
2023-11-01
4
M
false
1023
0
D
2029-02-08
Common Stock
1023
53144
D
Stock option (right to buy)
11.35
2023-11-02
4
M
false
3977
0
D
2029-02-08
Common Stock
3977
49167
D
Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.08 to $28.1244. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Fully exercisable.
/s/ Joseph Douglas Lyon
2023-11-03